Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Receivables: 2021-2024

Historic Change in Receivables for Keros Therapeutics (KROS) over the last 4 years, with Dec 2024 value amounting to $2.6 million.

  • Keros Therapeutics' Change in Receivables fell 3309.38% to -$12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 700.00%. This contributed to the annual value of $2.6 million for FY2024, which is 1717.48% up from last year.
  • Latest data reveals that Keros Therapeutics reported Change in Receivables of $2.6 million as of FY2024, which was up 1,717.48% from $143,000 recorded in FY2023.
  • Keros Therapeutics' 5-year Change in Receivables high stood at $18.0 million for FY2021, and its period low was -$18.0 million during FY2022.
  • For the 3-year period, Keros Therapeutics' Change in Receivables averaged around -$5.1 million, with its median value being $143,000 (2023).
  • In the last 5 years, Keros Therapeutics' Change in Receivables crashed by 200.00% in 2022 and then spiked by 1,717.48% in 2024.
  • Yearly analysis of 4 years shows Keros Therapeutics' Change in Receivables stood at $18.0 million in 2021, then crashed by 200.00% to -$18.0 million in 2022, then spiked by 100.79% to $143,000 in 2023, then skyrocketed by 1,717.48% to $2.6 million in 2024.